Resverlogix Corp. (TSX: RVX CN)

Resverlogix Corp. (TSX: RVX CN), a leading biotechnology company, is committed to developing innovative therapies designed to address the unmet needs of important global medical markets. The company’s NexVas™ program is mainly focused on developing novel small molecules that enhance ApoA-I. Resverlogix’s second focus is on relieving the dreadful burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s disease and other vascular disorders. For further information, visit the Company’s web site at www.resverlogix.com.